TRCT
TLIS

Tower Research Capital (TRC)’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Tower Research Capital (TRC)’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-877
Closed -$7.6K – 6091
2024
Q2 		$7.6K Sell
877
-50
-5% -$443 ﹤0.01% 4447
2024
Q1 		$8.11K Sell
927
-61
-6% -$503 ﹤0.01% 4078
2023
Q4 		$7.36K Buy
988
+208
+27% +$1.35K ﹤0.01% 4621
2023
Q3 		$4.5K Buy
780
+762
+4,233% +$5.21K ﹤0.01% 4857
2023
Q2 		$131 Sell
18
-17
-49% -$123 ﹤0.01% 5786
2023
Q1 		$0 Buy
+35
New +$298 ﹤0.01% 6442
2022
Q4 		– Sell
-280
Closed -$3K – 6530
2022
Q3 		$3K Buy
+280
New +$3.54K ﹤0.01% 5448
2022
Q2 		– Sell
-1,051
Closed -$22K – 6663
2022
Q1 		$22K Buy
1,051
+678
+182% +$23.5K ﹤0.01% 3460
2021
Q4 		$22K Sell
373
-525
-58% -$39.3K ﹤0.01% 3581
2021
Q3 		$85K Buy
898
+820
+1,051% +$109K ﹤0.01% 2532
2021
Q2 		$13K Sell
78
-554
-88% -$94.1K ﹤0.01% 4249
2021
Q1 		$122K Buy
+632
New +$158K ﹤0.01% 2439

Other funds holding TLIS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Tower Research Capital (TRC)'s TLIS Position: Q3 2024 in Review

Tower Research Capital (TRC) sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q3 2024, closing a stake of 877 shares — an estimated $7.6K sold.

Tower Research Capital (TRC) first reported a position in TLIS in Q1 2021 and held it in 12 quarters. The position peaked at $122K in Q1 2021. 2 funds tracked by Wall St. Rank hold TLIS as of Q3 2024.

  • Tower Research Capital (TRC) reported no remaining Talis Biomedical Corporation Common Stock position as of Q3 2024 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 877 Talis Biomedical Corporation Common Stock shares in Q3 2024, an estimated $7.6K.
  • Tower Research Capital (TRC) first reported a position in Talis Biomedical Corporation Common Stock in Q1 2021 and held it in 12 quarters.
  • Tower Research Capital (TRC)'s Talis Biomedical Corporation Common Stock position peaked at $122K in Q1 2021.
  • 2 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q3 2024.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2024, filed 14 Nov 2024.